Rx for Biotech

Gene therapy offers significant hope for treating sickle cell disease (SCD), a genetic disorder caused by a single mutation in the hemoglobin gene. Recent advancements have led to promising developments and FDA approvals, but challenges remain. In this podcast episode, gene therapy survivor, Jimi Olaghere, shares his journey and offers hope to others with his inspirational message and through his advocacy for patients in the sickle cell community.

In this podcast episode, hear from Diakonos Oncology President and Chief Operating Officer Jay Hartenbach, who provides an update on the company's innovative dendritic cell vaccine therapy designed to tackle some of the most challenging cancers, including glioblastoma and pancreatic cancer

Dr. Thomas Chen is a world-renowned neurosurgeon, Director of Surgical Neuro-Oncology at the University of Southern California, and the founder and CEO of NeOnc Technologies. In this podcast episode we discuss the company’s unique approach to treating glioblastoma and other aggressive brain cancers.

Our guest in this podcast episode is Sreekanth Gopi, a leader in generative AI and machine learning. Sreekanth has applied AI to fields as diverse as physiological monitoring, meditation, and even generating multi-track Indian classical music. He’s published award-winning research on EEG spectral analysis and adaptive quiz generation using large language models, participated in over 12 AI hackathons—winning two—and is now a Prompt Engineer at Morgan Stanley, where he fine-tunes cutting-edge LLM interactions for real-world applications.

In this episode we explore how AI is redefining stress management and revolutionizing real-time physiological data applications. Tune in to learn about the world of generative artificial intelligence— and looking at its transformative potential in mental health and stress management.

Arvinas is a biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. In this podcast episode, Dr. Randy Teel discusses the company's PROTAC protein degrader technology platform and its pipeline of clinical-stage assets, with a focus on vepdegestrant, the company's lead asset that is being co-developed together with partner Pfizer, for the treatment of women with early and locally advanced or metastatic ER+/HER2- breast cancer.

HLTH brings together all the ecosystem stakeholders each year to discuss the innovations that will help solve some of healthcare's biggest challenges. In this podcast episode, Noe Gutierrez, the Head of Commercial Operations at Genoplex, Inc., shares many of the key themes and insights from the biggest health tech conference of 2024.

Next Generation Gene Therapies is developing novel gene therapies for the treatment of many rare diseases. In this podcast episode, the company's Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company's dual-functional vector tech platform is being used to target many diseases.

Immunotherapies continue to redefine treatment for many types of cancer and one of the first immunotherapies approved and used clinically as a therapeutic is Interleukin-2, or IL-2.

Aulos Bioscience is an immuno-oncology company that has developed AU-007, a potential best-in-class IL-2, that improves on many of the other IL-2 products in development. In this episode, we discuss the promise of AU-007 with President and CEO, Aron Knickerbocker.

Link to Interleukin-2 review article can be found here: https://www.nature.com/articles/s41587-022-01390-3

In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease.

Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases.

Link to NMOSD video mentioned in episode:

https://www.youtube.com/playlist?list=PLJQx_6LtucSB9GGeiWTycLm7wjK_LX0ZI

In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma.

Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.